Treatment
Sacituzumab tirumotecan clinical trials
We’re tracking 39 recruiting studies that include Sacituzumab tirumotecan, each written for real people, not researchers, below.
Recruiting studies
- NCT07068542Recruiting
New drug combo for advanced thyroid cancer
This trial tests a new drug called sacituzumab tirumotecan combined with immunotherapy for people with advanced thyroid cancer that cannot be removed by surgery or has spread. It aims to see if this combination can help shrink tumors or slow down the cancer.
Hangzhou, ZhejiangAges 18 years+ - NCT07438626RecruitingPhase 2
Sacituzumab tirumotecan for SMARCB1-deficient kidney cancer
This trial tests an investigational drug called sacituzumab tirumotecan for a rare and aggressive type of kidney cancer called renal medullary carcinoma (RMC) or a related variant. The drug is designed to target and deliver treatment directly to cancer cells. The study aims to see if it can shrink tumors or slow the disease in people who have already tried other treatments.
Houston, TexasAges 18 years+ - NCT07419295RecruitingPhase 3
Testing a new drug for advanced bladder cancer
This trial is for people with advanced bladder cancer (urothelial cancer) that has spread or can't be removed. It tests a new drug called sacituzumab tirumotecan against standard chemotherapy options to see if it works better.
Washington D.C., District of ColumbiaAges 18 years+ - NCT07105852RecruitingPhase 2
A new drug combo for advanced bile duct cancer
This trial tests a combination of two drugs, sacituzumab tirumotecan and pucotenlimab, for people with advanced bile duct cancer (including gallbladder cancer) that cannot be removed by surgery or has spread. The goal is to see if this treatment is safe and works well, especially for those with a protein called TROP2 on their cancer cells.
Hangzhou, ZhejiangAges 18 years+ - NCT07850791RecruitingPhase 2
Study of two drugs for advanced bile duct or gallbladder cancer
This trial tests a combination of two drugs, sacituzumab tirumotecan and pembrolizumab, for people with advanced bile duct or gallbladder cancer that has grown after previous treatment. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Beijing, Beijing MunicipalityAges 18–75 - NCT07324629RecruitingPhase 2
Sacituzumab Tirumotecan for advanced thymus cancer
This trial tests a new drug, sacituzumab tirumotecan, in people with advanced thymic carcinoma that has spread or cannot be removed with surgery. It is for those whose cancer has gotten worse after at least one round of platinum-based chemotherapy.
ShanghaiAges 18–75 - NCT06637423RecruitingPhase 1/Phase 2
Study of sacituzumab tirumotecan for low-grade bladder cancer
This trial tests a new drug called sacituzumab tirumotecan for people with low-grade bladder cancer that hasn't spread into the bladder muscle. The goal is to see if it can help shrink or control the tumors.
Bakersfield, CaliforniaAges 18 years+ - NCT07785609RecruitingPhase 2
New drug combination for advanced solid tumors
This trial tests a new drug combination for people with advanced solid tumors. It aims to see if the combination is safe and may shrink tumors.
San Antonio, TexasAges 18 years+ - NCT07088211RecruitingPhase 2
New drug combo for first-line head and neck cancer
This trial tests a new drug combination (sacituzumab tirumotecan and toripalimab) as a first treatment for people with advanced head and neck squamous cell carcinoma that cannot be removed with surgery. The goal is to see if this treatment shrinks tumors and improves outcomes.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07375316RecruitingPhase 2
Combination therapy for EGFR-mutated lung cancer with lingering ctDNA
This trial tests if adding sacituzumab tirumotecan to osimertinib works better than osimertinib alone for advanced lung cancer that still shows cancer DNA (ctDNA) in the blood after initial osimertinib treatment.
Guangzhou, GuangdongAges 18 years+ - NCT06393374RecruitingPhase 3
Study of a new drug combination for residual TNBC after initial treatment
This trial tests a new combination of two drugs (sacituzumab tirumotecan and pembrolizumab) compared to standard chemotherapy for people with triple-negative breast cancer that did not fully respond to initial treatment. It aims to see if this combination helps prevent cancer from coming back.
Mobile, AlabamaAges 18 years+ - NCT07718854RecruitingPhase 2
Study of two drugs for advanced ovarian clear cell cancer
This study tests two investigational drugs, alone or together, for advanced ovarian clear cell cancer that has not responded to usual treatments. The goal is to see if these drugs help shrink or control the cancer.
Boston, MassachusettsAges 18 years+ - NCT07216703RecruitingPhase 3
Study of sacituzumab tirumotecan plus pembrolizumab for cervical cancer
This trial tests a combination of two drugs (sacituzumab tirumotecan and pembrolizumab) as a first maintenance treatment for cervical cancer that has spread or come back. It is for people who haven't had other cancer treatments for this stage and whose tumors have a certain protein marker (PD-L1).
Birmingham, AlabamaAges 18 years+ - NCT06992739RecruitingPhase 2
Trilaciclib with chemotherapy for EGFR-mutant advanced lung cancer
This study tests whether adding trilaciclib to a new chemotherapy (sacituzumab tirumotecan) can help people with EGFR-mutant lung cancer that keeps growing after certain targeted treatments. The goal is to see if it slows the cancer and reduces side effects.
Xiamen, FujianAges 18–75 - NCT06966700RecruitingPhase 3
Study of Sac-TMT in Early High-Risk Breast Cancer
This study tests a new drug called Sacituzumab Tirumotecan (Sac-TMT) for people with early-stage, high-risk breast cancer that hasn't spread. The drug is given before surgery to see if it can shrink tumors and improve outcomes.
Gilbert, ArizonaAges 18 years+ - NCT07323056RecruitingPhase 2
Neoadjuvant drug combo for stage 3 EGFR-mutant lung cancer
This trial tests two drugs, sacituzumab tirumotecan and limertinib, given before surgery to people with stage 3 non-small cell lung cancer that has an EGFR mutation. The goal is to see if this combination can shrink the tumor enough to allow surgery.
ShanghaiAges 18 years+ - NCT06312137RecruitingPhase 3
Pembrolizumab with or without another drug for lung cancer after surgery
This trial tests adding a new drug (sacituzumab tirumotecan) to pembrolizumab for people with non-small cell lung cancer that did not completely disappear after initial treatment and surgery. The goal is to see if the combination works better than pembrolizumab alone.
Little Rock, ArkansasAges 18 years+ - NCT07329322RecruitingPhase 2
Drug combo before surgery for EGFR-mutated lung cancer
This trial tests a combination of two targeted drugs (sacituzumab tirumotecan and osimertinib) before surgery for people with a specific type of lung cancer (EGFR-mutated). The goal is to see if the drugs can shrink the tumor enough to improve surgery results.
BeijingAges 18–75 - NCT06841354RecruitingPhase 3
Sac-TMT alone or with pembrolizumab for advanced triple-negative breast cancer
This trial tests a new drug, Sac-TMT, given alone or with an immunotherapy drug (pembrolizumab) for people with advanced triple-negative breast cancer who have not yet received any treatment for advanced disease. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Mobile, AlabamaAges 18 years+ - NCT06824467RecruitingPhase 3
Maintenance Therapy Study for Recurrent Ovarian Cancer
This study tests a new maintenance treatment (sacituzumab tirumotecan) versus standard care for people with ovarian cancer that has come back after responding to platinum-based chemotherapy. The goal is to see if it can keep the cancer from growing longer and improve quality of life.
Birmingham, AlabamaAges 18 years+ - NCT07548060RecruitingPhase 2
New drug combination for advanced lung cancer after prior treatments
This trial tests two newer drugs (sacituzumab tirumotecan and furmonertinib) together for patients with advanced non-squamous lung cancer whose tumors have specific genetic mutations and have stopped responding to earlier EGFR-targeted drugs and chemotherapy. The goal is to find out if this combination can help patients whose cancer has progressed.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT07179783RecruitingPhase 2
Sacituzumab Tirumotecan and Tagitanlimab for aggressive prostate cancer
This trial tests a combination of two drugs for men with aggressive or neuroendocrine prostate cancer that has worsened after previous hormone therapy. The goal is to see if the combination can shrink tumors or slow the disease.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06952504RecruitingPhase 3
Comparing two drug combos for advanced endometrial cancer
This trial tests a new drug combination (sacituzumab tirumotecan plus pembrolizumab) against pembrolizumab alone for people with a specific type of advanced or recurrent endometrial cancer that has normal mismatch repair function. It aims to see which treatment works better.
Mobile, AlabamaAges 18 years+ - NCT06312176RecruitingPhase 3
Study of new drugs for HR+/HER2- advanced breast cancer
This trial tests two new drugs (sacituzumab tirumotecan and pembrolizumab) against standard treatments for a type of advanced breast cancer that is hormone receptor positive and HER2 negative. It's for people whose cancer has worsened despite hormone therapy with a CDK4/6 inhibitor.
Chandler, ArizonaAges 18 years+
What Sacituzumab tirumotecan is being studied for
Conditions with recruiting Sacituzumab tirumotecan studies.
Common questions
- Are there clinical trials studying Sacituzumab tirumotecan?
- Yes. Clin2 currently lists 39 recruiting studies that include Sacituzumab tirumotecan, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Sacituzumab tirumotecan trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Sacituzumab tirumotecan an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Sacituzumab tirumotecan or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.